Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide when given with peripheral stem cell transplantation and to see how well they work in treating children with newly diagnosed malignant glioma or recurrent CNS tumors or other solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Head and Neck Cancer Kidney Cancer Neuroblastoma Ovarian Cancer Sarcoma Testicular Germ Cell Tumor |
Biological: filgrastim Drug: temozolomide Procedure: peripheral blood stem cell transplantation |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors |
- Overall response at 12 months [ Designated as safety issue: No ]
- Disease-free survival at 12 months [ Designated as safety issue: No ]
- Toxicity by NCI Common Toxicity Criteria v. 3.0 at 12 months [ Designated as safety issue: Yes ]
- Engraftment related to autologous marrow or peripheral blood stem cell transplantation at 12 months [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | August 2000 |
| Study Completion Date: | November 2005 |
| Primary Completion Date: | November 2005 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine the maximum tolerated dose of temozolomide in children with newly diagnosed malignant glioma or recurrent CNS or other solid tumors.
- Evaluate the toxicity of this treatment in these patients.
- Determine the activity of this treatment in these patients.
OUTLINE: This is a dose escalation study of temozolomide.
Patients receive filgrastim (G-CSF) subcutaneously (SQ) or IV beginning on day -5 and continuing through at least day 3. Peripheral blood stem cells (PBSC) are collected on days 0, 2, and 4. Patients then receive oral temozolomide daily for 5 consecutive days. PBSC collections are reinfused 1 day after the last dose of temozolomide. Patients also receive G-CSF beginning at the time of transplant and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities.
Patients are followed every 3 months for 1-3 years, then annually thereafter.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 12 months.
Eligibility| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Histologically confirmed newly diagnosed malignant glioma or recurrent malignant CNS tumor of any pathology OR
Histologically confirmed non-CNS tumor
- Recurrent soft tissue sarcomas (e.g., rhabdomyosarcoma)
- Recurrent or resistant neuroblastoma
- Recurrent Wilm's tumor
- Recurrent Ewing's sarcoma
- Recurrent primitive neuroectodermal tumors
- Recurrent nasopharyngeal carcinoma
- Recurrent germ cell tumor
- Expected cure rate less than 10% with standard therapy
- Measurable and/or active disease
- History of bone marrow tumor infiltration with or without mass lesions or isolated abnormal CSF cytology as only evidence of recurrent disease allowed if complete response was first achieved with primary conventional therapy
PATIENT CHARACTERISTICS:
Age:
- 18 and under
Performance status:
- Karnofsky 70-100% OR
- Lansky 70-100%
Life expectancy:
- Greater than 8 weeks
Hematopoietic:
- Reasonably cellular bone marrow (greater than 15% cellularity on biopsy)
- Absolute neutrophil count greater than 1,000/mm^3
- Platelet count greater than 75,000/mm^3
Hepatic:
- Bilirubin less than 2.0 mg/dL
- SGPT less than 120 U/L
Renal:
- Creatinine less than 1.5 mg/dL
Cardiovascular:
- Systolic fraction or ejection fraction at least 80% predicted for age by echocardiogram
Pulmonary:
- CVC or DLCO at least 60% predicted for age OR clearance from pulmonologist
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No active infection
- Able to tolerate vigorous hydration schedule
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent white blood cell transfusion
- No other concurrent hematopoietic growth factors
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- No other concurrent cytotoxic drugs (systemic or intrathecal)
Endocrine therapy:
- Concurrent corticosteroids allowed
Radiotherapy:
- See Disease Characteristics
- At least 1 week since prior radiotherapy
Surgery:
- At least 1 week since prior surgery
Other:
- No other concurrent investigational agents
Contacts and Locations| United States, North Carolina | |
| Duke Comprehensive Cancer Center | |
| Durham, North Carolina, United States, 27710 | |
| Study Chair: | Henry S. Friedman, MD | Duke Cancer Institute |
More Information
Additional Information:
No publications provided
| Responsible Party: | Duke University |
| ClinicalTrials.gov Identifier: | NCT00005952 History of Changes |
| Other Study ID Numbers: | CDR0000067932, DUMC-1735-04-9R5, DUMC-1735-02-9R3, DUMC-1735-01-9R2, DUMC-1833-99-10, NCI-G00-1796 |
| Study First Received: | July 5, 2000 |
| Last Updated: | February 15, 2013 |
| Health Authority: | United States: Federal Government Duke University Health System Institutional Review Board |
Keywords provided by Duke University:
|
childhood low-grade cerebral astrocytoma recurrent childhood rhabdomyosarcoma childhood craniopharyngioma disseminated neuroblastoma stage 4S neuroblastoma recurrent neuroblastoma stage IV Wilms tumor stage V Wilms tumor recurrent Wilms tumor and other childhood kidney tumors childhood central nervous system germ cell tumor stage III malignant testicular germ cell tumor recurrent malignant testicular germ cell tumor stage IV nasopharyngeal cancer recurrent nasopharyngeal cancer childhood germ cell tumor |
metastatic childhood soft tissue sarcoma recurrent childhood soft tissue sarcoma stage IV ovarian germ cell tumor recurrent ovarian germ cell tumor childhood high-grade cerebral astrocytoma childhood oligodendroglioma childhood choroid plexus tumor untreated childhood brain stem glioma recurrent childhood brain stem glioma untreated childhood supratentorial primitive neuroectodermal tumor recurrent childhood supratentorial primitive neuroectodermal tumor untreated childhood cerebellar astrocytoma recurrent childhood cerebellar astrocytoma recurrent childhood cerebral astrocytoma untreated childhood medulloblastoma |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Kidney Neoplasms Head and Neck Neoplasms Nervous System Neoplasms Neuroblastoma Ovarian Neoplasms Central Nervous System Neoplasms Neoplasms, Germ Cell and Embryonal Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral Sarcoma Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Nervous System Diseases Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Nerve Tissue Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female |
ClinicalTrials.gov processed this record on May 16, 2013